Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses, Drug Design Development and Therapy, November 2015, Dove Medical Press,
DOI: 10.2147/dddt.s87653.
You can read the full text:

Open access logo


The following have contributed to this page